Welcome to our dedicated page for Goodrx Holdings news (Ticker: GDRX), a resource for investors and traders seeking the latest updates and insights on Goodrx Holdings stock.
GoodRx Holdings, Inc. (NASDAQ: GDRX) is widely described as the leading platform for medication savings in the U.S., and its news flow reflects that role at the intersection of digital healthcare, pharmacy, and pharmaceutical manufacturers. Company announcements highlight new partnerships, product launches, and financial updates that shape how consumers, pharmacies, and manufacturers approach prescription affordability.
News about GoodRx often covers collaborations with major healthcare players. Examples include the RxSmartSaver program powered by GoodRx at national and regional retail pharmacies, which brings brand medication savings directly to the pharmacy counter, and an exclusive partnership with Surescripts that integrates GoodRx discounted cash prices into Script Corner, a patient experience product focused on prescription price transparency.
GoodRx also issues press releases on new consumer offerings and subscriptions. Recent updates describe GoodRx for Weight Loss, a telemedicine subscription for GLP-1 weight management treatment, and GoodRx for Hair Loss, a subscription program for men that combines virtual consultations, prescriptions for oral finasteride or oral minoxidil when appropriate, and discreet home delivery. Additional news highlights defined cash prices for medications such as Repatha, Ozempic, Wegovy, and the Wegovy pill at tens of thousands of pharmacies nationwide via GoodRx.
Investors and observers can also find earnings-related news, including quarterly financial results, guidance commentary, and participation in healthcare conferences. Together, these updates provide insight into GoodRx’s strategy across prescription transactions, subscriptions, pharma manufacturer solutions, and telehealth. For anyone tracking GDRX, this news page offers a focused view of how the company is evolving its platform, expanding partnerships, and addressing medication affordability across the U.S. healthcare system.
GoodRx (NASDAQ: GDRX), America's leading medication savings platform, has appointed Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. Jensen joins from Amazon Pharmacy, where she served as Head of Manufacturer & Prescriber Business Development, bringing extensive experience in pharmaceutical partnerships and patient access innovation.
Jensen will lead GoodRx's Pharma Manufacturer Solutions division, leveraging her background at companies like UCB and GlaxoSmithKline to enhance pharmaceutical partnerships. GoodRx, which has helped Americans save over $85 billion on medications since 2011, serves nearly 30 million consumers and over one million healthcare professionals annually.
GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025 after market close.
The company will host a conference call and webcast on Thursday, August 7, 2025 at 5:00 AM PT (8:00 AM ET) to discuss the quarterly results and business outlook. Interested participants must pre-register to receive dial-in details. The webcast will be available on the company's investor relations website, with materials posted before the call and an archived version accessible for at least 30 days afterward.
GoodRx (NASDAQ: GDRX) announced the launch of GoodRx Community Link, a new offering for independent community pharmacies, set to debut in June 2025. The platform will enable locally owned pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). The initiative implements cost-plus models to provide independent pharmacies with enhanced control over pricing and improved margins.
GoodRx, which serves nearly 30 million consumers and over 1 million healthcare professionals annually, has helped Americans save over $85 billion on medication costs since 2011. The company will host informational webinars on June 3 and 4, 2025, featuring Aaron Crittenden, President of Rx Marketplace, to discuss the new program with independent pharmacy teams.
GoodRx, the leading platform for medication savings in the U.S., has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. markets close on Wednesday, May 7, 2025.
A conference call and webcast with GoodRx management will follow on Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and business outlook. Interested parties can pre-register for the conference call through a provided link to receive dial-in details and a unique passcode.
The call will be webcast live on the company's investor relations website, where presentation materials will be available before the conference. An archived version of the webcast will remain accessible for at least 30 days after the call.
GoodRx (NASDAQ: GDRX) has launched a new e-commerce experience for retail pharmacies, partnering with Midwest retailer Hy-Vee as their initial collaborator. The platform enhances the prescription fulfillment process by:
The system now checks medication inventory, validates prescriptions, and enables online payment before in-store pickup. This innovation aims to streamline pharmacy workflows and improve consumer experience.
According to Wendy Barnes, President and CEO of GoodRx, this initiative addresses friction points at pharmacy counters while supporting retail pharmacy efficiency and profitability. The platform includes features like inventory verification, prescription validation, and flexible payment options including pay-over-time.
This development follows GoodRx's previous e-commerce launch with Opill, the first over-the-counter birth control pill, demonstrating the company's commitment to simplifying healthcare access. GoodRx currently serves nearly 30 million consumers and over one million healthcare professionals annually.
GoodRx (Nasdaq: GDRX), the leading medication savings platform in the U.S., has announced two key executive appointments. Aaron Crittenden has been named President of Rx Marketplace, while Scott Pope, PharmD, becomes Chief Pharmacy Officer and Head of Clinical Engagement.
Crittenden, who joined GoodRx in 2020, will manage the Rx Marketplace offering and work with retail pharmacy, PBM, employer, and manufacturer partners. As former Head of Manufacturer Solutions and Chief Revenue Officer, he helped grow revenue to over $100M. Pope brings nearly 30 years of healthcare experience and will oversee relationships with healthcare professionals, including marketing and product development.
GoodRx serves nearly 30 million consumers and over one million healthcare professionals annually. Since 2011, the platform has helped Americans save over $85 billion on medication costs by connecting consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies.
GoodRx (GDRX) has released a report revealing significant gender disparities in prescription medication costs. In 2024, women spent $8.8 billion more than men on out-of-pocket prescription costs, representing a 30% higher expenditure.
Key findings show women spent nearly $40 billion in total out-of-pocket prescription costs, with female-specific conditions exceeding $1.5 billion. The gender gap is most pronounced among women aged 18-44, who spend up to 64% more than men of the same age group. Women also outspend men significantly on mental health treatments, paying 113% more for depression medications and 103% more for anxiety treatments.
To address this disparity, GoodRx offers savings at over 70,000 pharmacies nationwide, including discounts up to 43% on fertility treatments and special pricing for menopause therapies ($99-$249 range).